🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Proud of the work the TIL_WorkingGroup Group does and the great collaborations we have built. Check out ourly newly launched website! Krishna Komanduri, MD, FASTCT Omid Hamid MD Adam J. Schoenfeld John Haanen

🚨New paper alert: Next-Generation Sequencing for HLA Genotype Screening and Matching to HLA-Restricted Therapies jamanetwork.com/journals/jamao…. Mike V. Gormally, MD PhD Adam J. Schoenfeld MSK Department of Medicine

🔬 New from our group in @JAMAOncology: Germline HLA genotyping must become standard as #HLA restricted therapies expand. Crucial for #Immunotherapy and #PrecisionOncology Monica Chen Adam J. Schoenfeld Klebanoff_Lab 🧵1/8 jamanetwork.com/journals/jamao…

📊 Our large-scale HLA study called germline HLA genotypes for ~60K patients from MSK-IMPACT—the largest HLA dataset in clinically-annotated cancer patients. 3/8

✔️ Validation: Despite not being formally targeted by the NGS panel, HLA calls inferred from POLYSOLVER show near-perfect concordance with CLIA-certified testing. #Genomics 4/8

🚀 Real-world application: Trial screening efficiency jumped from 4/31 to 14/14 HLA-matched patients. Breaking barriers to access cancer immunotherapies. 5/8

🧑‍🔬On the horizon at the bench: Watch for future work led by Chai Bandlamudi & Klebanoff_Lab diving into HLA loss of heterozygosity amongst this same 60K-patient cohort. 7/8

🏥 On the horizon in the clinic: Many new HLA-restricted trials in 2025, majority public #neoantigen-specific #TCR-T, including #MSKCC's first #KRAS #TCR-T produced in-house Adam J. Schoenfeld #ACT 8/8

Mucinous lung adenocarcinoma (LUAD-Muc) is a WHO-recognized rare subtype of LUAD. Our study in Annals of Oncology aimed to characterize clinicopathologic, genomic, immunophenotypic & transcriptional features differentiating these tumors form other LUADs 1/9 annalsofoncology.org/article/S0923-…

The OncoAlert 🚨Newsletter NOW OUT Covering September November 28-Dec 5, 2024 REGISTER AT OncoAlert360.com OR buff.ly/48Xpgz0 Discussing ✅FDA Approves Duvalumab in #SCLC 🫁🇺🇸 ✅FDA ACCELERATED APPROVAL TO ZENOCUTUZUMAB-ZBCO IN #NSCLC 🫁 ✅Lung

check out this month's special issue of transplantation and cellular therapy focused on TIL! enjoyed reviewing the clinical journey to date in melanoma with Allison Betof Warner, MD, PhD and Adam J. Schoenfeld sciencedirect.com/science/articl…

Cracking TP53! Mike V. Gormally, MD PhD from Memorial Sloan Kettering Cancer Center presents on TCR gene therapy for undruggable TP53 hotspot mutations at #iwCART25. A new frontier in targeting solid tumors? 🧬🛠️ #TP53 #TCRtherapy #ImmunoOncology

Bravo Mike V. Gormally, MD PhD 🙌! Memorial Sloan Kettering Cancer Center MSK Department of Medicine #Tcellpower

Come check out our poster tomorrow on whole-exome sequencing of colitis adverse events in patients treated with immune checkpoint inhibitors #AACR25 Elad Ziv Dr. Melinda Aldrich, MPH, PhD Adam J. Schoenfeld Christine Lovly, MD, PhD, FASCO

Research fellow Mike V. Gormally, MD PhD will present results of a real-world analysis that evaluated HLA LOH frequencies & survival outcomes in cancer. Memorial Sloan Kettering Cancer Center AACR #AACR25 Learn more: bit.ly/44Ij39Y Session starts at 2:30 p.m. CT | Presentation at 3:05 p.m. CT

Posters at #ASCO25 are starting now! Medical oncologist Rohit Thummalapalli will present a study that evaluated delta-like ligand 3 as an emerging target in gastroenteropancreatic neuroendocrine neoplasms. Memorial Sloan Kettering Cancer Center ASCO Learn more: bit.ly/3Fy3J5N

Congratulations to Kathryn Arbour Kathryn C. Arbour and colleagues showing activity of BMS-986504 in MTAP-deleted solid tumors, including lung and pancreas cancer. Memorial Sloan Kettering Cancer Center

Double trouble! Congrats to Rosh on his important work showing that bridging RT prior to CAR T cells is safe and probably needs greater personalization by tumor genetics. Great work! Memorial Sloan Kettering Radiation Oncology Memorial Sloan Kettering Cancer Center #18ICML